Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049893 · ClinicalTrials.gov registry record · Phase 1
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT01049893: Completed Phase 1 study of Solid Tumors, sponsored by Daiichi Sankyo.
NCT01049893 is a Phase 1 study of Solid Tumors that has completed, run by Daiichi Sankyo. The registered enrollment target is 45 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01049893, a Phase 1 study of Solid Tumors, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe adverse events (AEs) related to the study drug.
Conditions Studied
Interventions
- DRUG Compound AC220
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
Texas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
What the finished NCT01049893 record still lists
NCT01049893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Compound AC220 is the first listed.
NCT01049893 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT01049893 about?
NCT01049893 is a clinical study titled "Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors". AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe adverse events (AEs) related to the study drug.
What is the current status of trial NCT01049893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-01. Estimated completion is 2011-11.
What conditions does trial NCT01049893 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT01049893?
The interventions under investigation include: Compound AC220 (DRUG).
Who is sponsoring clinical trial NCT01049893?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049893 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01049893's enrollment target sits among peer trials
45 86th of 125 higher than 38 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia